Brief: Diasorin Gets Clearance From Fda For Second Blood Infection Panel On Liaison Plex
22/04/2025 10:02
April 22 (Reuters) - DiaSorin SpA DIAS.MI: RECEIVED CLEARANCE FROM U.S. FDA FOR SECOND BLOOD INFECTION PANEL ON LIAISON PLEX LIAISON PLEX PART OF THREE PANELS OF MULTIPLEX MOLECULAR TESTS FOR IDENTIFYING BLOODSTREAM INFECTIONS DETECTS 27 TARGETS, INCLUDING 19 GRAM-NEGATIVE PATHOGENIC BACTERIA, RESISTANCE GENES, COMPLETES CURRENT DIAGNOSTIC WORK-UP, REDUCES OPERATIONAL COSTS Further company coverage: DIAS.MI (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on DiaSorin SpA
See all newsKepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick
Brief: Diasorin Receives Us' FDA 510(K) Clearance And Clia Waiver For Liaison Nes Group A Streptococcus (Gas) Assay
Deutsche Bank cuts Diasorin to 'sell', sees company targets as stretched
Italy - Factors to watch on June 5
Italy's DiaSorin jumps after Betaville reports possible takeover interest